French data reveals which arthritis drug better shields patients from heart attacks and strokes
NCT ID NCT07459335
Summary
This study used French national health records to compare two medications—tocilizumab and methotrexate—for treating giant cell arteritis, a serious inflammatory condition. Researchers looked at over 1,600 patients to see which drug was better at preventing major heart problems like heart attacks, strokes, and death. The goal was to understand which treatment offers better long-term protection for patients' cardiovascular health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP_ Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
APHP_ Hôpital Saint-Antoine
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.